Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **small-molecule combination procedural kit** containing dexamethasone sodium phosphate injection, lidocaine hydrochloride injection, povidone-iodine swabsticks, and isopropyl alcohol prep pads. The therapeutic pharmacology is driven primarily by dexamethasone sodium phosphate, a rapidly acting water-soluble synthetic glucocorticoid ester that exerts anti-inflammatory effects through activation of the glucocorticoid receptor and downstream transcriptional regulation, and by lidocaine hydrochloride, a local anesthetic that blocks voltage-gated sodium channels to inhibit nerve impulse conduction. Povidone-iodine and isopropyl alcohol serve as topical antiseptic skin-preparation components rather than systemic therapeutic agents. The product has been marketed as Dexlido and distributed by Enovachem Pharmaceuticals for use as a packaged kit accompanying dexamethasone and lidocaine injection administration across labeled corticosteroid-responsive and procedural-use settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone sodium phosphate + lidocaine hydrochloride + povidone-iodine + isopropyl alcohol.